Tuman R W, Morris D M, Wallace N H, Bowden C R
Department of Biological Research, Janssen Research Foundation, Spring House, Pennsylvania 19477-0776.
J Clin Endocrinol Metab. 1991 Apr;72(4):755-60. doi: 10.1210/jcem-72-4-755.
R 76713 (6-[(4-chlorophenyl)(1-H-1,2,4-trizol-1-yl)methyl]1-H benzotriazole) is a highly potent and selective inhibitor of the aromatase enzyme both in vitro and in vivo. The ability of R 76713 to inhibit peripheral aromatization of androstenedione (A) to estrone (E1) in vivo was studied in male cynomolgus monkeys (Macaca fascicularis). Peripheral aromatization was measured using a primed constant infusion of [3H] A and [14C]E1 for 3.5 h. Blood samples, collected during the final hour of infusion, were analyzed for plasma radioactivity as infused and product steroids. MCRs, conversion ratios (CR), and percent conversion of A to E1 were calculated. R 76713 (0.03-10 microgram/kg) or vehicle (10% hydroxypropyl-beta-cyclodextrin) were administered iv 90 min before beginning the infusion of radiolabeled steroids. In vehicle-treated monkeys, the aromatization of A (mean +/- SEM, 1.35 +/- 0.11%) was similar to that previously reported for cynomolgus and rhesus monkeys, baboons, and humans. Aromatization of A, measured 4-5 h after injection of R 76713, was dose-dependently decreased from the control value by 87 +/- 3%, 85 +/- 2%, 61 +/- 5%, and 33 +/- 8% (all P less than 0.05) at doses of 10.0, 3.0, 0.3, and 0.03 micrograms/kg, respectively, with an ID50 of 0.13 microgram/kg, iv (95% confidence interval, 0.06-0.21). When measured 15-16 h after iv administration of 3.0 micrograms/kg R 76713, aromatization (0.55 +/- 0.13%) was significantly inhibited by 53 +/- 11% compared to that in control monkeys (1.16 +/- 0.18%). The CRs between androgens, the CRs between estrogens, and the MCRs of A and E1 were not significantly altered by R 76713 compared to those after vehicle treatment. R 76713 potently decreased peripheral conversion of androgen to estrogen in vivo in male cynomolgus monkeys and may be a useful therapeutic agent in treating estrogen-dependent diseases, including post-menopausal breast cancer.
R 76713(6-[(4-氯苯基)(1-H-1,2,4-三唑-1-基)甲基]-1-H-苯并三唑)在体外和体内都是一种高效且选择性的芳香化酶抑制剂。在雄性食蟹猴(猕猴)中研究了R 76713在体内抑制雄烯二酮(A)外周芳香化转化为雌酮(E1)的能力。外周芳香化通过对[3H]A和[14C]E1进行预充注并持续恒速输注3.5小时来测定。在输注的最后一小时采集血样,分析其中作为输注物的血浆放射性以及产物类固醇。计算代谢清除率(MCRs)、转化率(CR)以及A转化为E1的百分比。在开始输注放射性标记类固醇前90分钟静脉注射R 76713(0.03 - 10微克/千克)或赋形剂(10%羟丙基-β-环糊精)。在接受赋形剂处理的猴子中,A的芳香化(均值±标准误,1.35±0.11%)与先前报道的食蟹猴、恒河猴、狒狒和人类的情况相似。在注射R 76713后4 - 5小时测定,A的芳香化在剂量为10.0、3.0、0.3和0.03微克/千克时,分别比对照值剂量依赖性地降低了87±3%、85±2%、61±5%和33±8%(所有P均小于0.05),静脉注射的半数抑制剂量(ID50)为0.13微克/千克(95%置信区间,0.06 - 0.21)。在静脉注射3.0微克/千克R 76713后15 - 16小时测定,芳香化(0.55±0.13%)与对照猴子(1.16±0.18%)相比显著抑制了53±11%。与赋形剂处理后相比,R 76713对雄激素之间的CRs、雌激素之间的CRs以及A和E1的MCRs没有显著改变。R 76713在体内能有效降低雄性食蟹猴中雄激素向雌激素的外周转化,可能是治疗包括绝经后乳腺癌在内的雌激素依赖性疾病的一种有用治疗剂。